Radiopharm Theranostics updates CFO and secretaries

Radiopharm Theranostics Limited reports leadership changes in its finance and corporate governance functions.

Rhea-AI Filing Summary

Radiopharm Theranostics Limited reports leadership changes in its finance and corporate governance functions. Mr Phillip Hains has resigned as Chief Financial Officer and Joint Company Secretary. Under the company’s service agreement with Acclime Australia, Mr Aaron Laurita has been nominated to assume the Chief Financial Officer role.

The company has also appointed Ms Amritha Sushil of Acclime Australia as a new Joint Company Secretary, joining existing Joint Company Secretary Mr Nathan Jong. Both Ms Sushil and Mr Jong will be responsible for communications between Radiopharm Theranostics and the ASX. These changes take effect immediately.

Key Figures

Effective date of changes: 1 May 2026 Joint Company Secretaries: 2 joint company secretaries Service provider: Acclime Australia engagement

3 metrics

Effective date of changes 1 May 2026 Date of ASX announcement on finance and company secretary changes

Joint Company Secretaries 2 joint company secretaries Amritha Sushil and Nathan Jong responsible for ASX communications

Service provider Acclime Australia engagement Provides company secretarial, CFO and financial services under ongoing agreement

Key Terms

ASX Listing Rule 3.16.1, Joint Company Secretary, company secretarial, corporate governance and compliance

4 terms

ASX Listing Rule 3.16.1 regulatory

"provides an update in accordance with ASX Listing Rule 3.16.1"

Joint Company Secretary financial

"Mr Phillip Hains was engaged as Chief Financial Officer and Joint Company Secretary"

company secretarial financial

"to provide company secretarial, CFO and statutory reporting, accounting"

corporate governance and compliance financial

"Ms Sushil has extensive experience in corporate governance and compliance"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership changes did Radiopharm Theranostics (RADX) announce in this Form 6-K?

Radiopharm Theranostics announced that Phillip Hains resigned as Chief Financial Officer and Joint Company Secretary. Acclime Australia has nominated Aaron Laurita as the new CFO, and Amritha Sushil has been appointed Joint Company Secretary alongside existing secretary Nathan Jong.

Who is the new Chief Financial Officer of Radiopharm Theranostics (RADX)?

Radiopharm Theranostics’ CFO responsibilities will be performed by Aaron Laurita of Acclime Australia. He brings finance and commercial experience across multiple sectors, including biotechnology, in Australia, the United States and Canada, and is a qualified Chartered Accountant with a Bachelor of Business from RMIT University.

Who are the Joint Company Secretaries for Radiopharm Theranostics (RADX)?

Radiopharm Theranostics confirmed that Amritha Sushil and Nathan Jong of Acclime Australia will serve as Joint Company Secretaries. They are responsible for communications between the company and the ASX, with Ms Sushil bringing extensive corporate governance and compliance experience to the role.

Does Radiopharm Theranostics (RADX) continue its arrangement with Acclime Australia?

Yes. Radiopharm Theranostics continues its agreement with Acclime Australia for company secretarial, CFO, accounting, financial management, bookkeeping and payroll services. Under this arrangement, Acclime nominated Aaron Laurita as CFO and provides Joint Company Secretaries Amritha Sushil and Nathan Jong to support governance requirements.

When do the finance and company secretary changes at Radiopharm Theranostics (RADX) take effect?

The company stated that the changes to the Chief Financial Officer and Joint Company Secretaries take effect immediately. The accompanying announcement was dated 1 May 2026, indicating the new appointments and responsibilities commenced without a transition period noted in the disclosure.

Which listing rule governs these disclosed changes at Radiopharm Theranostics (RADX)?

The company noted that the update was provided in accordance with ASX Listing Rule 3.16.1. This rule generally requires prompt market disclosure of changes to key positions such as directors or certain senior officers, ensuring investors are informed about important governance changes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 08:00 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2026

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on May 1, 2026 titled:

“Financial Services and Company Secretary Changes”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Financial Services and Company Secretary Changes

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: May 1, 2026	By:	/s/ Nathan Jong
		Nathan Jong
		Company Secretary

3

Exhibit 99.1

ASX ANNOUNCEMENT 1 May 2026

Financial Services and Company Secretary Changes

Sydney, Australia – 1 May 2026 – Radiopharm Theranostics (ASX: RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical needs advises, provides an update in accordance with ASX Listing Rule 3.16.1.

As disclosed in the Company’s annual reporting, it has a continuing agreement with Acclime Australia to provide company secretarial, CFO and statutory reporting, accounting and financial management, bookkeeping and payroll processing services. Under this agreement, Mr Phillip Hains was engaged as Chief Financial Officer and Joint Company Secretary.

The Company advises that Mr Hains has resigned from his roles as Chief Financial Officer and Joint Company Secretary. The Board thanks Mr Hains for his contribution to the Company and wishes him well in his future plans.

The Company will continue to engage Acclime Australia to provide these services, and Acclime Australia has nominated Mr Aaron Laurita to perform the responsibilities of Chief Financial Officer. Mr Laurita brings strong finance and commercial expertise, developed through working with organisations across several sectors, including the biotechnology sector, in Australia, the United States and Canada over the past decade. Mr Laurita holds a Bachelor of Business (Professional Accountancy) from RMIT University and is a qualified Chartered Accountant and a member of Chartered Accountants Australia and New Zealand.

The Company is also pleased to announce the appointment of Ms Amritha Sushil of Acclime Australia as Joint Company Secretary. Ms Sushil has extensive experience in corporate governance and compliance, and the Board looks forward to her support in this role. Ms Sushil is a Chartered Secretary and an Associate of the Governance Institute of Australia.

Mr Nathan Jong of Acclime Australia continues in his role as a Joint Company Secretary.

For the purposes of ASX Listing Rule 12.6, the Company confirms that Ms Amritha Sushil and Mr Nathan Jong will serve as Joint Company Secretaries and will be responsible for communications between the Company and ASX.

These changes take effect immediately.

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889

ASX ANNOUNCEMENT 1 May 2026

Anne Marie Fields

Precision AQ (Formerly Stern IR)

E: annemarie.fields@precisionaq.com

Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media
Matt Wright
NWR Communications

P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/

Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 FINANCIAL SERVICES AND COMPANY SECRETARY CHANGES 10.0 KB